Recombinant poxviruses for cancer immunotherapy

Patent metadata

Field	Value
Publication number	US-12252702-B2
Application number	US-201917275974-A
Country	US
Kind code	B2
Filing date	Sep 16, 2019
Priority date	Sep 15, 2018
Publication date	Mar 18, 2025
Grant date	Mar 18, 2025

Abstract

Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof. In particular aspects, the present technology relates to the use of genetically engineered or recombinant poxviruses, including a modified vaccinia Ankara (MVA) virus comprising a deletion of E3L (MVAΔE3L) engineered to express OX40L (MVAΔE3L-OX40L), an MVA virus comprising a deletion of C7L (MVAΔC7L) engineered to express OX40L (MVAΔC7L-OX40L), a MVAΔC7L engineered to express OX40L and human Fms-like tyrosine kinase 3 ligand (hFlt3L) (MVAΔC7L-hFlt3L-OX40L), an MVA comprising a deletion of E5R (MVAΔE5R), a vaccinia virus comprising a deletion of C7L (VACVΔC7L) engineered to express OX40L (VACVΔC7L-OX40L), a VACVΔC7L engineered to express both OX40L and hFlt3L (VACVΔC7L-hFlt3L-OX40L), a VACV comprising a deletion of E5R (VACVΔE5R), a myxoma virus (MYXV) comprising a deletion of M31R (MYXVΔM31R), or combinations thereof, alone or in combination with other agents, as an oncolytic and immunotherapeutic composition.

First claim

What is claimed is:

1. A modified vaccinia Ankara (MVA) virus genetically engineered to comprise a knocked out E5R gene (MVAΔE5R) and a knocked out E3L gene (ΔE3L) (MVAΔE5RΔE3L).

2. The MVAΔE5RΔE3L virus of claim 1 , wherein the virus further comprises one or more heterologous nucleic acid molecules encoding one or more of OX40L, hFlt3L, hIL-2, hIL-12, hIL-15, hIL-15/IL-15Rα, hIL-18, IL-21, anti-huCTLA-4, anti-huPD-1, anti-huPD-L1, GITRL, 4-1BBL, or CD40L, and/or a knockout of any one or more of thymidine kinase (ΔTK), C7 (ΔC7L), B2R (ΔB2R), WR200, K7R, C12L, B8R, B14R, N1L, C11R, K1L, M1L, N2L, or WR199.

3. The MVAΔE5RΔE3L virus of claim 2 , wherein, when the virus further comprises one or more heterologous nucleic acids, the heterologous nucleic acids are expressed from within one or more viral genes selected from the group consisting of the thymidine kinase (TK) gene, the C7 gene, the C11 gene, the K3 gene, the F1 gene, the F2 gene, the F4 gene, the F6 gene, the F8 gene, the F9 gene, the F11 gene, the F14.5 gene, the J2 gene, the A46 gene, the E3L gene, the WR200 gene, the E5R gene, the K7R gene, the C12L (IL18BP) gene, the B8R gene, the B14R gene, the N1L gene, the K1L gene, the C16 gene, the M1L gene, the N2L gene, and the WR199 gene.

4. The MVAΔE5RΔE3L virus of claim 1 , wherein the knocked out E5R gene comprises replacement of at least a portion of the E5R gene with one or more gene cassettes comprising one or more heterologous nucleic acid molecules.

5. An immunogenic composition comprising the MVAΔE5RΔE3L virus of claim 1 .

6. The immunogenic composition of claim 5 , further comprising a pharmaceutically acceptable carrier and/or adjuvant.

7. A nucleic acid sequence encoding the MVAΔE5RΔE3L virus of claim 1 .

8. A kit comprising the MVAΔE5RΔE3L virus of claim 1 and instructions for use thereof.

9. A method for treating a tumor in a subject in need thereof, the method comprising delivering to a tumor a composition comprising an effective amount of the MVAΔE5RΔE3L virus of claim 1 , wherein the virus further comprises a heterologous nucleic acid molecule encoding hFlt3L and a heterologous nucleic acid molecule encoding hOX40L (MVAΔE3LΔE5R-hFlt3L-hOX40L).

10. The method of claim 9 , wherein the treatment comprises one or more of the following: inducing an immune response in the subject against the tumor or enhancing or promoting an ongoing immune response against the tumor in the subject, reducing the size of the tumor, eradicating the tumor, inhibiting the growth of the tumor, inhibiting metastatic growth of the tumor, inducing apoptosis of tumor cells of the tumor, or prolonging survival of the subject.

11. The method of claim 9 , wherein the composition is administered by intratumoral or intravenous injection or a simultaneous or sequential combination of intratumoral and intravenous injection.

12. The method of claim 9 , wherein the tumor is melanoma, colon, breast, bladder, prostate carcinoma, or Extramammary Paget disease (EMPD).

13. The method of claim 9 , wherein the method further comprises separately, sequentially, or simultaneously administering to the subject one or more immune checkpoint blocking agents selected from anti-PD-L1 antibody, anti-PD-1 antibody, or anti-CTLA-4 antibody.

14. The MVAΔE5RΔE3L virus of claim 1 , wherein the knocked out E5R and the knocked out E3L gene comprise replacement of at least a portion of the E5R gene and the E3L gene with one or more gene cassettes comprising one or more heterologous nucleic acid molecules.

15. The MVAΔE5ΔE3L virus of claim 1 , wherein the virus further comprises a heterologous nucleic acid molecule encoding hOX40L (MVAΔE3LΔE5R-hOX40L).

16. The MVAΔE5RΔE3L virus of claim 1 , wherein the virus further comprises a heterologous nucleic acid molecule encoding hFlt3L, and a heterologous nucleic acid molecule encoding hOX40L (MVAΔE3LΔE5R-hFlt3L-hOX40L).

17. The MVAΔE5RΔE3L virus of claim 16 , wherein the virus further comprises one or more heterologous nucleic acid molecules encoding one or more of hIL-2, hIL-15, hIL-15/IL-15Rα, hIL-18, hIL-21, anti-huCTLA-4, anti-huPD-1, anti-huPD-L1, GITRL, 4-1BBL, or CD40L, and/or a knockout of any one or more of thymidine kinase (ΔTK), C7 (ΔC7L), B2R (ΔB2R), WR200, IL18BP, K7R, C12L, B8R, B14R, N1L, C11R, K1L, M1L, N2L, or WR199.

18. The MVAΔE5RΔE3L virus of claim 1 , wherein the virus further comprises a heterologous nucleic acid molecule encoding hFlt3L, a heterologous nucleic acid molecule encoding hOX40L, and a knocked out WR199 gene (ΔWR199) (MVAΔE3LΔE5R-hFlt3L-hOX40LΔWR199).

19. A modified vaccinia Ankara (MVA) virus genetically engineered to comprise a knocked out E5R gene (MVAΔE5R) and a knocked out E3L gene (ΔE3L), a heterologous nucleic acid molecule encoding hFlt3L, a heterologous nucleic acid molecule encoding hOX40L, a heterologous nucleic acid molecule encoding hIL-12, and a knocked out WR199 gene (ΔWR199) (MVAΔE3LΔE5R-hFlt3L-hOX40LΔWR199-hIL-12).

20. The MVAΔE3LΔE5R-hFlt3L-hOX40LΔWR199-hIL-12 virus of claim 19 , wherein the virus further comprises one or more heterologous nucleic acid molecules encoding one or more of hIL-2, hIL-15, hIL-15/IL-15Rα, hIL-18, hIL-21, anti-huCTLA-4, anti-huPD-1, anti-huPD-L1, GITRL, 4-1BBL, or CD40L, and/or a knockout of any one or more of thymidine kinase (ΔTK), C7 (ΔC7L), B2R (ΔB2R), WR200, IL18BP, K7R, C12L, B8R, B14R, N1L, C11R, K1L, M1L, or N2L.

21. An immunogenic composition comprising the MVAΔE3LΔE5R-hFlt3L-hOX40LΔWR199-hIL-12 virus of claim 19 .

22. The immunogenic composition of claim 21 , further comprising a pharmaceutically acceptable carrier and/or adjuvant.

23. A nucleic acid sequence encoding the MVAΔE3LΔE5R-hFlt3L-hOX40LΔWR199-hIL-12 virus of claim 19 .

24. A kit comprising the MVAΔE3LΔE5R-hFlt3L-hOX40LΔWR199-hIL-12 virus of claim 19 and instructions for use thereof.

Assignees

• Memorial Sloan Kettering Cancer Center

Inventors

• Deng Liang
• Wolchok Jedd
• Shuman Stewart
• Merghoub Taha
• Yang Ning
• Wang Yi
• Mazo Gregory
• Dai Peihong
• Wang Weiyi

Classifications

• C12N2710/24143

  viral genome or elements thereof as genetic vector · CPC title

• C12N2710/24134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• C07K16/2818

  against CD28 or CD152 · CPC title

• C07K14/71

  for growth factors; for growth regulators · CPC title